Form 4: Royalty Pharma Director Ted W. Love Receives Stock Award

Director Ted W. Love of Royalty Pharma plc reports acquisition of 7,614 Class A Ordinary Shares through a restricted stock unit award.

Summary

• Ted W. Love, a director of Royalty Pharma plc, reported a transaction on May 13, 2025, where he acquired 7,614 Class A Ordinary Shares.
• The acquisition was due to an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan.
• These restricted stock units are scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date.
• Following the transaction, Love directly owns 53,848 Class A Ordinary Shares.
• The transaction was signed by Sean Weisberg, as Attorney-in-Fact for Ted W. Love, on May 14, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning director interests with shareholders.

Positives

• The award of restricted stock units aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The stock award aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.

Key Dates

Keywords

Royalty Pharma, Director, Ted W. Love, Stock Award, Class A Ordinary Shares, Restricted Stock Units, Equity Incentive Plan, Beneficial Ownership